학술논문
A single-arm, multi-center phase II study of tislelizumab combined with lenvatinib and GEMOX as conversion therapy in potentially resectable locally advanced biliary tract cancer (ZSAB-TransGOLP): A primary analysis.
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p488-488, 151p
Subject
Language
ISSN
0732183X